Metabolic Effects of Switching to Aripiprazole in Patients With Bipolar Disorders Having Drug-Induced Weight Gain.

Trial Profile

Metabolic Effects of Switching to Aripiprazole in Patients With Bipolar Disorders Having Drug-Induced Weight Gain.

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Sep 2016

At a glance

  • Drugs Aripiprazole (Primary) ; Clozapine; Olanzapine; Quetiapine; Risperidone
  • Indications Bipolar disorders
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 05 Jul 2012 Actual patient number is 28 according to ClinicalTrials.gov.
    • 05 Jul 2012 Actual end date (Mar 2012) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top